These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 525067

  • 41. Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia.
    Heel RC, Brogden RN, Speight TM, Avery GS.
    Drugs; 1977 Nov; 14(5):349-66. PubMed ID: 338280
    [Abstract] [Full Text] [Related]

  • 42. Disease-specific noncompliance with drug treatment as a cause of persistent hyperuricemia and gout in anorexia nervosa.
    Gröbner W, Walter-Sack I, de Vries JX.
    Eur J Med Res; 1998 Feb 21; 3(1-2):77-80. PubMed ID: 9512972
    [Abstract] [Full Text] [Related]

  • 43. Uricosuric effect of irtemazole in hyperuricemic patients without and with renal insufficiency.
    Kamilli I, Gresser U, Pellkofer T, Löffler W, Zöllner N.
    Z Rheumatol; 1989 Feb 21; 48(6):307-12. PubMed ID: 2623976
    [Abstract] [Full Text] [Related]

  • 44. [Clinical followup of the uricosuric drug--benzbromaron (author's transl)].
    Dzúrik R, Fedelesová V, Danĕková H, Hlavatá E.
    Bratisl Lek Listy; 1980 Nov 21; 74(5):547-54. PubMed ID: 7448590
    [No Abstract] [Full Text] [Related]

  • 45. The action of benzbromarone in relation to age, sex and accompanying diseases.
    Ferber H, Bader U, Matzkies F.
    Adv Exp Med Biol; 1980 Nov 21; 122A():287-94. PubMed ID: 6999850
    [Abstract] [Full Text] [Related]

  • 46. The efficacy of combined low dose of Allopurinol and benzbromarone compared to standard dose of Allopurinol in hyperuricemia.
    Akkasilpa S, Osiri M, Deesomchok U, Avihingsanon Y.
    J Med Assoc Thai; 2004 Sep 21; 87(9):1087-91. PubMed ID: 15516011
    [Abstract] [Full Text] [Related]

  • 47. [The use of Allomaron in treating hyperuricemia].
    Balkarov IM.
    Ter Arkh; 1994 Sep 21; 66(1):40-2. PubMed ID: 8146793
    [No Abstract] [Full Text] [Related]

  • 48. The pharmacology of hypouricemic effect of benzbromarone.
    Sinclair DS, Fox IH.
    J Rheumatol; 1975 Dec 21; 2(4):437-45. PubMed ID: 1206675
    [Abstract] [Full Text] [Related]

  • 49. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N.
    Arthritis Rheum; 2008 Nov 15; 59(11):1540-8. PubMed ID: 18975369
    [Abstract] [Full Text] [Related]

  • 50. [Results obtained with long-term benzbromarone therapy (author's transl)].
    Bresnik W, Müller MM.
    Wien Klin Wochenschr; 1974 May 17; 86(10):283-7. PubMed ID: 4428763
    [No Abstract] [Full Text] [Related]

  • 51. [Experience with benziodarone therapy in gout and hyperuricemic syndrome].
    Jorda V, Vykydal M, Pegrimová E, Bouvenot G.
    Beitr Rheumatol; 1972 May 17; 18():96-9. PubMed ID: 4649127
    [No Abstract] [Full Text] [Related]

  • 52. Benzbromarone as a long-term uricosuric agent.
    Bluestone R, Klinenberg J, Lee IK.
    Adv Exp Med Biol; 1980 May 17; 122A():283-6. PubMed ID: 6999849
    [No Abstract] [Full Text] [Related]

  • 53. [The uricosuric effect of benzbromaron and probenecid under fasting conditions (author's transl)].
    Schulz E, Schräpler P, Kleinschmidt A.
    Med Klin; 1978 Feb 17; 73(7):240-6. PubMed ID: 628361
    [Abstract] [Full Text] [Related]

  • 54. Does benzbromarone in therapeutic doses raise renal excretion of oxipurinol?
    Mertz DP, Eichhorn R.
    Klin Wochenschr; 1984 Dec 17; 62(24):1170-2. PubMed ID: 6530890
    [Abstract] [Full Text] [Related]

  • 55. [Clinical and biological effects of a new uric acid lowering substance (benziodaronum) in gout. Results of a 2-year-long study].
    Barcelo P, Santamaria A.
    Verh Dtsch Ges Rheumatol; 1969 Dec 17; 1():361-70. PubMed ID: 5403652
    [No Abstract] [Full Text] [Related]

  • 56. [Therapy of hyperuricemia and gout. Effect of a combination therapy of allopurinol with benzbromarone].
    Matzkies F.
    Fortschr Med; 1983 May 26; 101(20):953-9. PubMed ID: 6873850
    [No Abstract] [Full Text] [Related]

  • 57. [Study of amplivix in gout patients and nongouty arthrosic hyperuricemics].
    Doumerg C.
    Rhumatologie; 1968 Oct 26; 20(8):285-8. PubMed ID: 5712175
    [No Abstract] [Full Text] [Related]

  • 58. Gout--what are the treatment options?
    Schlesinger N, Dalbeth N, Perez-Ruiz F.
    Expert Opin Pharmacother; 2009 Jun 26; 10(8):1319-28. PubMed ID: 19463070
    [Abstract] [Full Text] [Related]

  • 59. A new potent hypouricemic drug. A clinical trial of the drug in a group of gouty patients.
    Serry MM.
    J Egypt Med Assoc; 1979 Jun 26; 62(1-2):255-61. PubMed ID: 400475
    [No Abstract] [Full Text] [Related]

  • 60. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
    Panomvana D, Sripradit S, Angthararak S.
    J Clin Rheumatol; 2008 Feb 26; 14(1):6-11. PubMed ID: 18431090
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.